STOCK TITAN

Innoviva (INVA) Stock Price, News & Analysis

INVA NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
2 252 sessions, November 18, 2025 to November 18, 2026
Largest daily move
-9.5% close of November 5, 2026
1-year change
-15.9% closing prices, November 18, 2025 to November 18, 2026
1-month change
-11.5% closing prices, October 16, 2026 to November 18, 2026

Company Description

Innoviva, Inc. (NASDAQ: INVA) is a diversified healthcare holding company with a focus on pharmaceutical preparation manufacturing and commercial-stage therapeutics. According to company disclosures, Innoviva combines a core royalties portfolio, a critical care and infectious disease platform operated through Innoviva Specialty Therapeutics, and a portfolio of strategic investments in healthcare assets. The company’s common stock is listed on the NASDAQ Global Select Market under the symbol INVA.

Innoviva’s royalties portfolio centers on respiratory assets partnered with Glaxo Group Limited (GSK). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. These royalty streams provide an ongoing revenue source that complements Innoviva’s operating businesses and investment activities.

Innoviva Specialty Therapeutics: Critical Care and Infectious Disease

Through its subsidiary Innoviva Specialty Therapeutics (IST), Innoviva is active in the development and commercialization of therapies for serious infections and critical care conditions. IST’s commercial portfolio, as described in company news releases, includes multiple FDA-approved medicines:

  • GIAPREZA® (angiotensin II), through the La Jolla Pharmaceutical Company affiliate, approved to increase blood pressure in adults with septic or other distributive shock.
  • XERAVA® (eravacycline), through La Jolla, approved for the treatment of complicated intra-abdominal infections in adults.
  • XACDURO® (sulbactam for injection; durlobactam for injection), through Entasis Therapeutics Inc., co-packaged for intravenous use and approved for adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex.
  • ZEVTERA® (ceftobiprole medocaril sodium for injection), an advanced-generation cephalosporin antibiotic approved in the U.S. for adult patients with Staphylococcus aureus bloodstream infections (bacteremia), including right-sided infective endocarditis, adult patients with acute bacterial skin and skin structure infections (ABSSSI), and adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP).

IST also develops and presents clinical, pharmacokinetic-pharmacodynamic, and microbiologic data across this portfolio, reflecting a focus on serious bacterial infections, drug-resistant pathogens, and critical care settings.

Zoliflodacin / NUZOLVENCE® and Gonorrhea Treatment

A key asset associated with Innoviva’s infectious disease platform is zoliflodacin, a first-in-class, single-dose, oral antibiotic from the spiropyrimidinetrione class. It has been developed as a treatment for uncomplicated urogenital gonorrhea, including infections caused by strains resistant to current first-line therapies. In collaboration with the Global Antibiotic Research & Development Partnership (GARDP), Innoviva Specialty Therapeutics supported a pivotal Phase 3, multinational, randomized, controlled trial that demonstrated non-inferiority of a single 3 g oral dose of zoliflodacin compared to ceftriaxone plus azithromycin in uncomplicated urogenital gonorrhea.

Innoviva reports that the U.S. Food and Drug Administration (FDA) granted zoliflodacin Qualified Infectious Disease Product (QIDP) designation, allowing Priority Review and extended market exclusivity. Subsequent disclosures describe FDA acceptance of a New Drug Application and assignment of a Prescription Drug User Fee Act (PDUFA) target action date. In later communications, Innoviva Specialty Therapeutics announced FDA approval of NUZOLVENCE® (zoliflodacin) for oral suspension as a first-in-class, single-dose oral medication for adults and pediatric patients 12 years and older weighing at least 35 kg with uncomplicated urogenital gonorrhea.

NUZOLVENCE is described as a bacterial type II topoisomerase inhibitor with a mechanism of action distinct from currently approved antibiotics and with demonstrated activity against drug-resistant Neisseria gonorrhoeae. Company materials also summarize key safety information, including contraindications, embryo-fetal toxicity warnings, potential testicular toxicity and fertility risks based on animal data, hypersensitivity reactions, Clostridioides difficile infection risk, and common adverse reactions such as headache, dizziness, nausea, and diarrhea.

Therapeutic Focus and Disease Areas

Across its specialty therapeutics platform, Innoviva concentrates on serious infectious diseases and critical care indications. Its marketed and pipeline assets address:

  • Drug-resistant gram-negative infections, including HABP/VABP due to susceptible Acinetobacter baumannii-calcoaceticus complex (XACDURO).
  • Gram-positive infections such as MRSA-related Staphylococcus aureus bacteremia, ABSSSI, and CABP (ZEVTERA).
  • Complicated intra-abdominal infections in adults (XERAVA).
  • Hemodynamic support in septic or other distributive shock (GIAPREZA).
  • Sexually transmitted infections, specifically uncomplicated gonorrhea, including drug-resistant strains (zoliflodacin/NUZOLVENCE).

Innoviva Specialty Therapeutics frequently presents clinical and pharmacologic data at major infectious disease meetings such as IDWeek, highlighting subgroup analyses, microbiologic surveillance, and PK-PD modeling for agents like zoliflodacin, ceftobiprole, sulbactam-durlobactam, and eravacycline.

Strategic Investments and Capital Allocation

Beyond royalties and marketed products, Innoviva maintains a portfolio of strategic healthcare investments held through various subsidiaries. Company reports reference investments in organizations developing therapies and technologies in areas such as infectious disease and neurotechnology. Innoviva also discloses activities such as term loans to development-stage companies and equity investments in private and public healthcare businesses.

Innoviva’s financial communications describe the company’s use of capital for share repurchase programs, debt management, and acquisitions of therapeutic assets and platforms, such as the acquisition of a long-acting oral drug delivery platform and related assets from Lyndra Therapeutics, Inc. These activities are presented as part of a broader capital allocation approach within its diversified holding company structure.

Stock Listing, Sector, and Regulatory Reporting

Innoviva’s common stock trades on the NASDAQ Global Select Market under the ticker INVA. The company is classified in the pharmaceutical preparation manufacturing industry within the broader manufacturing sector. Innoviva files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), including Form 8-K filings that furnish quarterly earnings press releases and other material information.

Stock Performance

$18.40
+0.00%
+0.00
Last updated: at
-15.9%
Performance 1 year

Innoviva (INVA) closed at $18.40 on November 18, 2026. Over the past 12 months, the price has lost 15.9%.

See what a $1,000 investment in INVA would be worth today

Average down calculator for INVA

INVA Metrics & Rankings

Price returns through November 18, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Financial Highlights

Innoviva generated $411.3M in revenue in FY2025, retaining a 74.8% gross margin, operating income reached $163.7M (39.8% operating margin), and net income was $271.2M, reflecting a 65.9% net profit margin. Diluted earnings per share stood at $3.30. The company generated $196.9M in operating cash flow. The current ratio was 14.64, measuring current assets divided by current liabilities.

$411.3M
Revenue (FY2025)
$271.2M
Net Income (FY2025)
$196.9M
Operating Cash Flow

Upcoming Events

No upcoming events scheduled for INVA.

Short Interest History

Last 12 Months

Short interest in Innoviva (INVA) currently stands at 7.5 million shares, up 3.2% from the previous reporting period, representing 10.7% of the float. Since November 2025, short interest has increased by 35.6%.

Days to Cover History

Last 12 Months

Days to cover for Innoviva (INVA) currently stands at 12.9 days, up 24.3% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 86.4%. Across the settlements charted above, it has ranged from 5.6 to 12.9 days.

INVA Company Profile & Sector Positioning

Innoviva (INVA) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing INVA often look at related companies in the same sector, including Novavax Inc (NVAX), LB Pharmaceuticals Inc (LBRX), Tyra Biosciences, Inc. (TYRA), AnaptysBio, Inc. (ANAB), and Mannkind Corporation (MNKD). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate INVA's relative position within its industry.

Frequently Asked Questions

The current stock price of Innoviva (INVA) is $18.40 as of November 19, 2026.

The market cap of Innoviva (INVA) is approximately $1.3B. Learn more about what market capitalization means .

The FY2025 revenue of Innoviva (INVA) is $411.3M, from its most recent completed fiscal year.

The FY2025 net income of Innoviva (INVA) is $271.2M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Innoviva (INVA) is $3.30 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Innoviva (INVA) is $196.9M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Innoviva (INVA) is 65.9% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Innoviva (INVA) is 39.8% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Innoviva (INVA) is 74.8% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Innoviva (INVA), current assets divided by current liabilities, was 14.64 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Innoviva (INVA) is $307.7M for FY2025, its most recent completed fiscal year.

The operating income of Innoviva (INVA) is $163.7M for FY2025, its most recent completed fiscal year. Learn about operating income.

Innoviva, Inc. is a diversified healthcare holding company that combines a royalties portfolio linked to GSK respiratory products, a critical care and infectious disease platform operated through Innoviva Specialty Therapeutics, and a portfolio of strategic investments in healthcare assets.

Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK). The company is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, providing a recurring revenue stream.

Innoviva Specialty Therapeutics is a subsidiary of Innoviva focused on delivering therapies in critical care and infectious disease. Through affiliates such as La Jolla Pharmaceutical Company and Entasis Therapeutics Inc., IST markets products including GIAPREZA, XERAVA, XACDURO, and ZEVTERA and advances assets such as zoliflodacin/NUZOLVENCE.

Company disclosures list several FDA-approved products: GIAPREZA for septic or other distributive shock, XERAVA for complicated intra-abdominal infections in adults, XACDURO for hospital-acquired and ventilator-associated bacterial pneumonia due to susceptible Acinetobacter, and ZEVTERA for Staphylococcus aureus bloodstream infections, ABSSSI in adults, and CABP in adults and certain pediatric patients.

Innoviva’s materials highlight warnings for embryo-fetal toxicity, potential risks related to male fertility and early pregnancy loss in partners, hypersensitivity reactions, Clostridioides difficile infection, and development of drug-resistant bacteria. Common adverse reactions include headache, dizziness, nausea, and diarrhea.

ZEVTERA is indicated in the U.S. for adult patients with Staphylococcus aureus bloodstream infections (bacteremia), including right-sided infective endocarditis, adult patients with acute bacterial skin and skin structure infections, and adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia caused by specified susceptible organisms.

Innoviva reports that it holds a portfolio of strategic healthcare assets through subsidiaries, including equity and long-term investments and term loans. These investments support companies developing therapies and technologies in areas such as infectious disease and neurotechnology, complementing Innoviva’s royalties and operating businesses.

Innoviva’s common stock is registered under Section 12(b) of the Securities Exchange Act and trades on the NASDAQ Global Select Market under the ticker symbol INVA.

Yes. Based on industry classification information provided, Innoviva operates in the pharmaceutical preparation manufacturing industry within the broader manufacturing sector, with a focus on therapeutic products and related healthcare assets.